


## PHARMACEUTICAL 2019



## Catalent Inc. Rank 23 of 371





## PHARMACEUTICAL 2019



## Catalent Inc. Rank 23 of 371

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 407% points. The greatest weakness of Catalent Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 225% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 514% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	1,240,300
Cost of Goods Sold	0
Intangible Assets	1,942,100
Liabilities, Current	576,900
Liabilities, Non-Current	0
Other Assets	78,100
Other Compr. Net Income	-11,700
Other Expenses	1,789,400
Other Liabilities	0
Other Net Income	-127,800
Property and Equipment	1,270,600
Research and Development	0
Revenues	2,463,400
Selling, General and Administrative Expense	462,600

Output Variable	Value in 1000 USD
Assets	4,531,100
Liabilities	576,900
Expenses	2,252,000
Stockholders Equity	3,954,200
Net Income	83,600
Comprehensive Net Income	77,750
Economic Capital Ratio	183%